Drug Trial Radar · NCT05728658
The Study of ICP-248 in Patients With Mature B-cell Malignancies
Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
191
Planned (sponsor's estimate)
Start
Mar 9, 2023
Primary completion
Aug 30, 2025
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients with Mature B-cell Malignancies.This study consists of two parts: Part 1 dose-finding period and Part 2 dose expansion period.
Conditions
- Hematological Malignancies
Interventions
ICP-248Drug
Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.
ICP-248Drug
Eligible patients will receive ICP-248 orally as specified in the treatment arm.
ICP-248+OrelabrutinibDrug
Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.
ICP-248+OrelabrutinibDrug
Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.
ICP-248 +RituximabDrug
Eligible patients will receive ICP-248 and Rituximab as specified in the treatment arm.
ICP-248+OrelabrutinibDrug
Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.
ICP-248+Orelabrutinib+RituximabDrug
Eligible patients will receive ICP-248 and Orelabrutinib and Rituximab as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose and recommended Phase 2 doseTime frame: 5 years
- To investigate the incidence, nature and severity of adverse events (AE) according to NCI-CTCAE V5.0 or iwCLL2018 evaluation criteria.Time frame: 5 years
- To evaluate the investigator-assessed overall response rate (ORR) of ICP-248 monotherapy or combination therapy at the recommended phase II dose (RP2D) .Time frame: 5 years
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China · Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Recruiting
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
The Central Hospital of Wuhan
Wuhan, Hubei, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Recruiting
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China · Recruiting
Shenyang Hospital Of China Medical University
Shenyang, Liaoning, China · Recruiting
Shandong cancer hospital
Jinan, Shandong, China · Recruiting
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Hematology Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China · Recruiting
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.